Eloralintide vs AICAR
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
EloralintideAnti-Aging & LongevityFat Loss & Metabolic
AICAR- Summary
- Eloralintide is a long-acting amylin analog under development by OPKO Health. Amylin is co-secreted with insulin and regulates post-meal glucose by slowing gastric emptying, suppressing glucagon, and promoting satiety. Eloralintide is designed for once-weekly dosing, differentiating it from the short-acting pramlintide (Symlin). It is being studied for obesity and type 2 diabetes as a complement to GLP-1 based therapies.
- AICAR is a cell-permeable AMP analog that activates AMPK (AMP-activated protein kinase) — the master metabolic switch that triggers fat burning, mitochondrial biogenesis, and adaptations normally only achieved through exercise. It has been called the 'exercise in a pill' compound.
- Half-Life
- ~7 days (estimated, long-acting design)
- ~2–3 hours
- Admin Route
- SubQ
- SubQ, IV
- Research
- —
- —
- Typical Dose
- Under investigation in Phase 1/2 trials
- 25–50 mg
- Frequency
- Once weekly
- 3–5 times per week
- Key Benefits
- Once-weekly dosing (vs multiple daily injections for pramlintide)
- Appetite suppression via central amylin receptor activation
- Reduction in post-meal glucagon secretion
- Complementary mechanism to GLP-1 agonists for combination therapy
- Slows gastric emptying for prolonged satiety
- Potential additive weight loss when combined with GLP-1 agents
- AMPK activation mimics aerobic exercise adaptations
- Increased fat oxidation and endurance
- Mitochondrial biogenesis (PGC-1alpha)
- Improved insulin sensitivity and glucose metabolism
- Anti-inflammatory effects
- Potential cardiac protection during ischemia
- Synergistic with actual exercise training
- Reduces hepatic glucose production
- Side Effects
- Nausea
- Vomiting
- Decreased appetite
- Injection site reactions
- +1 more
- Hypoglycemia risk
- Lactic acidosis at high doses (animal data)
- Injection site irritation
- Stacks With
- —
- —